TAS-303 / Otsuka - LARVOL DELTA

Breaking barriers in stress urinary incontinence care: TAS-303 as a game-changer in pharmacological innovation. (PubMed, Transl Androl Urol) - No abstract available

Journal • Urinary Incontinence • Urology

Re: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial. (PubMed, Eur Urol) - No abstract available

Clinical • Journal • P2 data • Urinary Incontinence • Urology

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence (clinicaltrials.gov) - P2 | N=337 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | Phase classification: P2a ➔ P2 | N=256 ➔ 337

Enrollment change • Phase classification • Urinary Incontinence • Urology

Reply: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, J Urol) - No abstract available

Clinical • Journal • P2 data • Urinary Incontinence • Urology

Letter: Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, J Urol) - No abstract available

Clinical • Journal • P2 data • Urinary Incontinence • Urology

Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, J Urol) - P2 | "Once-daily TAS-303 18 mg showed superior efficacy to placebo for the treatment of SUI in Japanese women, with an adequate safety profile. ClinicalTrials.gov: NCT04512053; Japan Registry of Clinical Trials: jRCT2080225307 (JapicCTI-205403 before site integration)."

Clinical • Journal • P2 data • Gastrointestinal Disorder • Urinary Incontinence • Urology • Women's Health

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Taiho Pharmaceutical Co., Ltd.

New P1 trial

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence (clinicaltrials.gov) - P2 | N=231 | Completed | Sponsor: Taiho Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: May 2022 ➔ Dec 2021 | Trial primary completion date: May 2022 ➔ Dec 2021

Trial completion • Trial completion date • Trial primary completion date • Urinary Incontinence • Urology

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence (clinicaltrials.gov) - P2; N=186; Active, not recruiting; Sponsor: Taiho Pharmaceutical Co., Ltd.; Recruiting ➔ Active, not recruiting

Enrollment closed • Urinary Incontinence • Urology

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence (clinicaltrials.gov) - P2; N=186; Recruiting; Sponsor: Taiho Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Urinary Incontinence • Urology

TAS-303 ameliorates carbachol-induced detrusor overactivity in rats, revealing its therapeutic potential for overactive bladder. (PubMed, J Pharmacol Exp Ther) - "TAS-303 has therapeutic potential for stress urinary incontinence. This study describes newly discovered pharmacological properties of TAS-303, which ameliorated bladder afferent activity partly via M3 muscarinic inhibition, indicating improvement in urge urinary incontinence, and study highlights the potential of TAS-303 as a new therapeutic agent for all types of urinary incontinence."

Journal • Preclinical • Constipation • Overactive Bladder • Urinary Incontinence • Xerostomia

Efficacy and safety of the noradrenaline reuptake inhibitor, TAS-303, in women with stress urinary incontinence: Results of a double-blind, randomized, placebo-controlled, early phase II trial. (PubMed, Int J Urol) - "These findings suggest that TAS-303 is effective for improving stress urinary incontinence symptoms in some subgroups of patients with stress urinary incontinence. Therefore, further research is warranted."

Clinical • Journal • P2 data • Cardiovascular • Urinary Incontinence • Urology • Women's Health

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence (clinicaltrials.gov) - P2; N=186; Not yet recruiting; Sponsor: Taiho Pharmaceutical Co., Ltd.

Clinical • New P2 trial • Urinary Incontinence